Goldman Sachs Group Inc Adicet Bio, Inc. Transaction History
Goldman Sachs Group Inc
- $580 Billion
- Q2 2024
A detailed history of Goldman Sachs Group Inc transactions in Adicet Bio, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 4,283,372 shares of ACET stock, worth $5.48 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,283,372
Previous 4,005,587
6.93%
Holding current value
$5.48 Million
Previous $9.41 Million
44.95%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding ACET
# of Institutions
92Shares Held
66.3MCall Options Held
4.3KPut Options Held
36.3K-
Orbimed Advisors LLC San Diego, CA11.4MShares$14.7 Million0.33% of portfolio
-
Tang Capital Management LLC San Diego, CA8.22MShares$10.5 Million1.21% of portfolio
-
Ra Capital Management, L.P. Boston, MA7.54MShares$9.65 Million0.14% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.62MShares$4.64 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.1MShares$3.97 Million0.0% of portfolio
About Adicet Bio, Inc.
- Ticker ACET
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,030,800
- Market Cap $51.2M
- Description
- Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune respo...